Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.

Hua L, Wakimoto H.

Expert Opin Biol Ther. 2019 Aug;19(8):845-854. doi: 10.1080/14712598.2019.1614557. Epub 2019 May 13.

PMID:
31046478
2.

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.

Ning J, Wakimoto H.

Front Microbiol. 2014 Jun 20;5:303. doi: 10.3389/fmicb.2014.00303. eCollection 2014. Review.

3.

Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.

Kahramanian A, Kuroda T, Wakimoto H.

Methods Mol Biol. 2019;1937:177-188. doi: 10.1007/978-1-4939-9065-8_10.

PMID:
30706396
4.

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.

Yin J, Markert JM, Leavenworth JW.

Front Oncol. 2017 Jun 26;7:136. doi: 10.3389/fonc.2017.00136. eCollection 2017. Review.

5.

Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.

Saha D, Martuza RL, Rabkin SD.

Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009.

6.

Oncolytic virus therapy: A new era of cancer treatment at dawn.

Fukuhara H, Ino Y, Todo T.

Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Review.

7.

The safety of talimogene laherparepvec for the treatment of advanced melanoma.

Gangi A, Zager JS.

Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28. Review.

PMID:
27989216
8.

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.

Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, Kaufman HL.

Expert Rev Anticancer Ther. 2015;15(12):1389-403. doi: 10.1586/14737140.2015.1115725. Review.

PMID:
26558498
9.

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.

Bommareddy PK, Patel A, Hossain S, Kaufman HL.

Am J Clin Dermatol. 2017 Feb;18(1):1-15. doi: 10.1007/s40257-016-0238-9. Review.

PMID:
27988837
10.

Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.

Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD.

J Virol. 2018 Jul 17;92(15). pii: e00246-18. doi: 10.1128/JVI.00246-18. Print 2018 Aug 1.

11.

Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.

Taguchi S, Fukuhara H, Todo T.

Jpn J Clin Oncol. 2018 Nov 20. doi: 10.1093/jjco/hyy170. [Epub ahead of print]

PMID:
30462296
12.

Talimogene laherparepvec (T-VEC) as cancer immunotherapy.

Kohlhapp FJ, Zloza A, Kaufman HL.

Drugs Today (Barc). 2015 Sep;51(9):549-58. doi: 10.1358/dot.2015.51.9.2383044. Review.

PMID:
26488034
13.

STAT3 activation promotes oncolytic HSV1 replication in glioma cells.

Okemoto K, Wagner B, Meisen H, Haseley A, Kaur B, Chiocca EA.

PLoS One. 2013 Aug 2;8(8):e71932. doi: 10.1371/journal.pone.0071932. Print 2013.

14.

The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.

Kloker LD, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B, Krieg A, Sipos B, Lauer UM.

Neuroendocrinology. 2019 Jun 13. doi: 10.1159/000500159. [Epub ahead of print]

PMID:
31280274
15.

Oncolytic herpes simplex virus and immunotherapy.

Ma W, He H, Wang H.

BMC Immunol. 2018 Dec 18;19(1):40. doi: 10.1186/s12865-018-0281-9. Review.

16.

Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.

Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y.

Semin Oncol. 2016 Dec;43(6):638-646. doi: 10.1053/j.seminoncol.2016.10.005. Epub 2016 Oct 27. Review.

PMID:
28061981
17.

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.

Braidwood L, Graham SV, Graham A, Conner J.

Oncolytic Virother. 2013 Dec 4;2:57-74. doi: 10.2147/OV.S52601. eCollection 2013. Review.

18.

Talimogene Laherparepvec: First Global Approval.

Greig SL.

Drugs. 2016 Jan;76(1):147-54. doi: 10.1007/s40265-015-0522-7.

PMID:
26620366
19.

Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT Jr.

Neurosurgery. 2012 Sep;71(3):741-8; discussion 748. doi: 10.1227/NEU.0b013e318260fd73.

20.

Oncolytic Virotherapy by HSV.

Watanabe D, Goshima F.

Adv Exp Med Biol. 2018;1045:63-84. doi: 10.1007/978-981-10-7230-7_4. Review.

PMID:
29896663

Supplemental Content

Support Center